Arrowstreet Capital, Limited Partnership Affimed N.V. Transaction History

Arrowstreet Capital, Limited Partnership

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$3.69 - $5.65 $260,609 - $399,036	-70,626 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$5.37 - $7.07 $2.15 Million - $2.83 Million	-400,540 Reduced 85.01%	70,626 $390,000
Q3 2021 Nov 12, 2021	BUY	$5.54 - $7.51 $2.61 Million - $3.54 Million	471,166 New	471,166 $2.91 Million
Q2 2021 Aug 13, 2021	SELL	$7.78 - $11.4 $3.63 Million - $5.32 Million	-466,693 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$5.12 - $8.48 $1.4 Million - $2.32 Million	-273,099 Reduced 36.92%	466,693 $3.69 Million
Q4 2020 Feb 12, 2021	BUY	$3.16 - $7.03 $2.34 Million - $5.2 Million	739,792 New	739,792 $4.31 Million
Q2 2020 Aug 12, 2020	SELL	$1.58 - $4.63 $45,404 - $133,052	-28,737 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$1.44 - $3.02 $220,975 - $463,434	-153,455 Reduced 84.23%	28,737 $45,000
Q4 2019 Feb 13, 2020	BUY	$2.25 - $3.07 $156,339 - $213,315	69,484 Added 61.65%	182,192 $499,000
Q3 2019 Nov 14, 2019	BUY	$2.67 - $3.65 $300,930 - $411,384	112,708 New	112,708 $331,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.